Preparation and pharmaceutical characterization of amorphous cefdinir using spray-drying and SAS-process

International Journal of Pharmaceutics

Volumn 396, Issue 1-2, 2010, Pages 239-245

  Park, Junsung ^a   Park, Hee Jun ^a   Cho, Wonkyung ^a   Cha, Kwang Ho ^a   Kang, Young Shin ^a   Hwang, Sung Joo ^a  

^a Chungnam National University   (South Korea)

Author keywords

Amorphous; Anhydrous; Cefdinir; Micronization; Supercritical anti solvent (SAS)

Indexed keywords

CEFDINIR; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; SOLVENT;

AMORPHORIZATION; ARTICLE; CHEMICAL PROCEDURES; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; INFRARED SPECTROSCOPY; LIGHT SCATTERING; MICRONIZATION; PARTICLE SIZE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; SUPERCRITICAL ANTISOLVENT PROCESS; THERMOGRAVIMETRY; X RAY POWDER DIFFRACTION; CHEMISTRY; KINETICS; MEDICINAL CHEMISTRY; NANOTECHNOLOGY; PHARMACEUTICS; POWDER DIFFRACTION; PROCEDURES; SOLUBILITY; SUPERCRITICAL FLUID CHROMATOGRAPHY; SURFACE PROPERTY; X RAY CRYSTALLOGRAPHY;

ANTI-BACTERIAL AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CEPHALOSPORINS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, SUPERCRITICAL FLUID; CRYSTALLOGRAPHY, X-RAY; KINETICS; MICROSCOPY, ELECTRON, SCANNING; NANOTECHNOLOGY; PARTICLE SIZE; POWDER DIFFRACTION; SOLUBILITY; SOLVENTS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL; THERMOGRAVIMETRY;

EID: 77955049147     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.06.032     Document Type: Article

References (26)

1. Al-Marzouqi A.H., Shehatta I., Jobe B., Dowaidar A. Phase solubility and inclusion complex of itraconazole with beta-cyclodextrin using supercritical carbon dioxide. J. Pharmaceut. Sci. 2006, 95:292-304.
2. Aleem O., Kuchekar B., Pore Y., Late S. Effect of [beta]-cyclodextrin and hydroxypropyl [beta]-cyclodextrin complexation on physicochemical properties and antimicrobial activity of cefdinir. J. Pharmaceut. Biomed. Anal. 2008, 47:535-540.
3. Bhattachar S.N., Wesley J.A., Fioritto A., Martin P.J., Babu S.R. Dissolution testing of a poorly soluble compound using the flow-through cell dissolution apparatus. Int. J. Pharm. 2002, 236:135-143.
4. Budavari S. The Merck Index 1996.
5. Cabri W., Ghetti P., Alpegiani M., Pozzi G., Justo-Erbez A., Perez-Martinez J.I., Villalón-Rubio R., Mondero-Perales C., Munoz-Ruiz A. Cefdinir: a comparative study of anhydrous vs. monohydrate form: microstructure and tabletting behaviour. Eur. J. Pharm. Biopharm. 2006, 64:212-221.
6. Chawla G., Bansal A.K. A comparative assessment of solubility advantage from glassy and crystalline forms of a water-insoluble drug. Eur. J. Pharmaceut. Sci. 2007, 32:45-57.
7. Chiou W.L., Reigelman S. Pharmaceutical applications of solid dispersion systems. J. Pharmaceut. Sci. 1971, 60:1281-1302.
8. Dhumal R.S., Biradar S.V., Yamamura S., Paradkar A.R., York P. Preparation of amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of bioavailability. Eur. J. Pharm. Biopharm. 2008, 70:109-115.
9. Di Martino P., Barthélémy C., Palmieri G.F., Martelli S. Physical characterization of naproxen sodium hydrate and anhydrate forms. Eur. J. Pharmaceut. Sci. 2001, 14:293-300.
10. Engel G.L., Farid N.A., Faul M.M., Richardson L.A., Winneroski L.L. Salt form selection and characterization of LY333531 mesylate monohydrate. Int. J. Pharm. 2000, 198:239-247.
11. Ford J.L., Elliott P.N.C. The effect of particle size on some in-vitro and in-vivo properties of indomethacin-polyethylene glycol 6000 solid dispersions. Drug Dev. Ind. Pharm. 1985, 11:537-549.
12. Han H.-K., Choi H.-K. Improved absorption of meloxicam via salt formation with ethanolamines. Eur. J. Pharm. Biopharm. 2007, 65:99-103.
13. Hancock B.C., Parks M. What is the true solubility advantage for amorphous pharmaceuticals?. Pharm. Res. 2000, 17:397-404.
14. Hancock B.C., Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharmaceut. Sci. 1997, 86:1-12.
15. Jun S.W., Kim M.-S., Kim J.-S., Park H.J., Lee S., Woo J.-S., Hwang S.-J. Preparation and characterization of simvastatin/hydroxypropyl-[beta]-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process. Eur. J. Pharm. Biopharm. 2007, 66:413-421.
16. Khankari R.K., Grant D.J.W. Pharmaceutical hydrates. Thermochim. Acta 1995, 248:61-79.
17. Kim E.-J., Chun M.-K., Jang J.-S., Lee I.-H., Lee K.-R., Choi H.-K. Preparation of a solid dispersion of felodipine using a solvent wetting method. Eur. J. Pharm. Biopharm. 2006, 64:200-205.
18. Kim J.-S., Kim M.-S., Park H.J., Jin S.-J., Lee S., Hwang S.-J. Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. Int. J. Pharm. 2008, 359:211-219.
19. Kim M.-S., Jin S.-J., Kin J.-S., Park H.J., Song H.-S., Neubert R.H.H., Hwang S.-J. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur. J. Pharm. Biopharm. 2008, 69:454-465.
20. Kim M.-S., Lee S., Park J.-S., Woo J.-S., Hwang S.-J. Micronization of cilostazol using supercritical antisolvent (SAS) process: effect of process parameters. Powder Technol. 2007, 177:64-70.
21. Linpinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 1997, 23:3-25.
22. Mahendru, M., Aryan, R., Chander, Kumar, S., Pandya, B., SanJam, D., Sanjay, G., Yatendra, K., 2006. Crystalline forms of cefdinir. WO/2006/018807, 23 February.
23. Park M.-J., Ren S., Lee B.-J. In vitro and in vivo comparative study of itraconazole bioavailability when formulated in highly soluble self-emulsifying system and in solid dispersion. Biopharm. Drug Dispos. 2007, 28:199-207.
24. Peeters J., Neeskens P., Tollenaere J.P., Remoortere P.V., Brewster M.E. Characterization of the interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4, and 7. J. Pharmaceut. Sci. 2002, 91:1414-1422.
25. Perrut M., Jung J., Leboeuf F. Enhancement of dissolution rate of poorly-soluble active ingredients by supercritical fluid processes. Part I. Micronization of neat particles. Int. J. Pharm. 2005, 288:3-10.
26. Perry C.M.S., Lesley J. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections. Drugs 2004, 64:1433-1464.